Psilocybe (genus) – mycolab.ai

Psilocybin’s effects on cognition and creativity: A scoping review

mycolabadmin

This comprehensive review examines how psilocybin affects thinking abilities and creativity. Researchers found that large doses initially impair mental performance during the experience, but small doses may enhance creativity. Importantly, the cognitive effects appear to improve after the acute effects wear off, suggesting initial impairment doesn’t cause lasting damage. The review emphasizes the need for more rigorous long-term studies to better understand psilocybin’s effects on brain function.

Exploring the neurobiological correlates of psilocybin-assisted psychotherapy in eating disorders: a review of potential methodologies and implications for the psychedelic study design

mycolabadmin

This review examines how psilocybin-assisted therapy might work for eating disorders by looking at various ways to measure changes in the brain. The authors discuss different brain imaging techniques and other tools that scientists could use to understand how psilocybin affects the brains of people with eating disorders. They emphasize that combining multiple measurement approaches provides the best understanding of how this emerging treatment works and can guide future research and clinical applications.

Psychedelic-Assisted Therapy: Potential Benefits and Challenges in Mental Health Treatment

mycolabadmin

This review examines how psychedelic substances like psilocybin and MDMA, when combined with professional psychotherapy, show promise in treating difficult-to-treat mental health conditions including depression, PTSD, and anxiety. While early research suggests these substances could help in cases where conventional treatments have failed, the evidence is still preliminary and limited by small study sizes. Psychedelics appear to work by changing how the brain processes information and memories, though much more rigorous research is needed before they can be considered standard treatments.

Psychological flexibility as a mechanism of change in psilocybin-assisted therapy for major depression: results from an exploratory placebo-controlled trial

mycolabadmin

This study examined how psilocybin mushroom therapy works for treating depression when combined with talk therapy. Participants received a placebo pill followed by psilocybin four weeks later, both times as part of psychological treatment. The research found that people who received psilocybin showed greater improvements in their ability to accept difficult thoughts and emotions and live according to their values, and these improvements were linked to feeling less depressed.

Mushrooms, Microdosing, and Mental Illness: The Effect of Psilocybin on Neurotransmitters, Neuroinflammation, and Neuroplasticity

mycolabadmin

This review examines how psilocybin, the active compound in certain mushrooms, may help treat depression and anxiety by reducing brain inflammation and promoting healthy neurotransmitter function. Both full doses under medical supervision and smaller ‘microdoses’ show promise for mental health conditions. The research suggests psilocybin works by calming the immune system’s inflammatory response while simultaneously supporting the brain’s natural healing and adaptation processes, offering a potential alternative treatment when standard medications don’t work.

Safety, tolerability, and clinical and neural effects of single-dose psilocybin in obsessive–compulsive disorder: protocol for a randomized, double-blind, placebo-controlled, non-crossover trial

mycolabadmin

This study tests whether psilocybin (the active compound in certain mushrooms) can help people with obsessive-compulsive disorder who haven’t responded to standard treatments. In a carefully controlled trial, participants receive either a single dose of psilocybin or a placebo while receiving psychological support, with their brain activity and symptoms monitored. The research aims to determine if this novel treatment is safe and whether it could work faster than existing medications for this difficult-to-treat condition.

The Potential Role of Psilocybin in Traumatic Brain Injury Recovery: A Narrative Review

mycolabadmin

This review examines how psilocybin, a compound found in certain mushrooms, may help people recover from traumatic brain injuries. The research suggests that psilocybin could reduce harmful inflammation in the brain, help the brain form new connections to compensate for damage, and improve mood and depression commonly experienced after brain injuries. While promising, the authors emphasize that more clinical trials are needed to confirm safety and effectiveness before psilocybin can be used to treat brain injury patients.

The Impact of Psilocybin on High Glucose/Lipid-Induced Changes in INS-1 Cell Viability and Dedifferentiation

mycolabadmin

Researchers tested whether psilocybin, a compound from magic mushrooms, could protect pancreatic β-cells (which produce insulin) from damage caused by high glucose and fat levels. Using laboratory cells, they found that psilocybin reduced β-cell death by preventing apoptosis and showed promise in reducing dedifferentiation (when cells lose their specialized functions). However, psilocybin didn’t restore the cells’ ability to respond to glucose by releasing insulin.

Multianalytical Investigation of Psilocybe cubensis Mushrooms: Physicochemical Characterization and Biological Evaluation of Psilocybin and Psilocin Compounds

mycolabadmin

Scientists extracted and analyzed psilocybin and psilocin from Psilocybe cubensis mushrooms to develop a medication for treating mental health disorders like depression and anxiety. Using various analytical techniques, they confirmed the extract contained about 3.26% psilocybin and was safe, pure, and stable. The research shows that creating a psilocybin-based medicine from these mushrooms is feasible and could offer a new treatment option for people struggling with mental health issues.

Fungal Species: Psilocybe (genus)